# 2025-21071: FDA Cuts Red Tape for Cancer Gene Tests, Patients Rejoice

2025-21071, Immunology and Microbiology Devices; Reclassification of Nucleic Acid-Based Test Systems for Use With a Corresponding Approved Oncology Therapeutic Product; Proposed Amendment; Proposed Order; Request for Comments, is a Federal Register proposed rule from Health and Human Services Department, Food and Drug Administration published 2025-11-25, effective Submit electronic or written comments on the proposed order by January 26, 2026. See section X of the document for the proposed effective date when the new requirements would apply and for the proposed effective date of a final order.; PRIA reads it as touching household money (as of 2026-06-11).

- Canonical: https://policyrisk.com/federal-register/2025-21071
- As of: 2026-06-11
- Plain-text twin of the page above; the HTML and this file carry the same facts.

## Facts
- Document number: 2025-21071
- Title: Immunology and Microbiology Devices; Reclassification of Nucleic Acid-Based Test Systems for Use With a Corresponding Approved Oncology Therapeutic Product; Proposed Amendment; Proposed Order; Request for Comments
- Type: Proposed Rule
- Agencies: Health and Human Services Department; Food and Drug Administration
- Citation: 90 FR 53261
- Published: 2025-11-25
- Effective: Submit electronic or written comments on the proposed order by January 26, 2026. See section X of the document for the proposed effective date when the new requirements would apply and for the proposed effective date of a final order.
- Comments close: not stated
- Significant: no
- Touches household money: yes
- Regulation identifier numbers: none
- Last updated: 2026-06-11

## In one line

FDA Cuts Red Tape for Cancer Gene Tests, Patients Rejoice

## Summary

The FDA wants to change the rules for certain cancer-related genetic test systems, making them easier to get approved by moving them from a strict Class III to a more flexible Class II category. This affects companies making these tests and could speed up how quickly patients get access to important cancer treatments. Comments on this change are open until January 26, 2026, so now’s the time to speak up!

## Abstract

The Food and Drug Administration (FDA) is proposing to reclassify certain postamendments class III nucleic acid-based test systems indicated for use with a corresponding approved oncology therapeutic product (product codes OWD, PJG, PQP, and SFL) from class III (premarket approval) into class II (special controls), subject to premarket notification. FDA is also proposing a new device classification regulation, along with the special controls that FDA believes are necessary to provide a reasonable assurance of safety and effectiveness for these devices.

## Effects PRIA read

- Class III → Class II: 510(k) Instead of PMA: benefit, high. The FDA proposes to reclassify certain nucleic acid-based oncology test systems (product codes OWD, PJG, PQP, and SFL) from Class III (PMA) to Class II (special controls). If finalized, manufacturers would no longer need a Premarket Approval (PMA) but must submit a premarket notification (510(k)) b…
- Faster Patient Access to Cancer Tests: benefit, high. FDA says reclassifying these oncology nucleic acid-based test systems to Class II and using the 510(k) pathway may result in shorter premarket review timelines and enable more manufacturers to develop these tests, which could provide more timely access to tests that guide cancer treatment decisions.
- Use of Predetermined Change Control Plans: benefit, medium. Manufacturers may use FDA-authorized predetermined change control plans (PCCPs) to implement future modifications described in an approved PCCP without submitting a new 510(k) or PMA supplement for each change, under section 515C of the FD&C Act (FDORA, enacted December 29, 2022).
- Prescription IVD Labeling Requirement: cost, low. If reclassified to Class II, these devices will be identified as prescription in vitro diagnostics (IVDs) and will be subject to prescription labeling requirements for IVD products (see 21 CFR 809.10(a)(4) and (b)(5)(ii)).

## Related documents

- [2026-20848](https://policyrisk.com/federal-register/2026-20848): Use of Salt Substitutes To Reduce the Sodium Content in Standardized Foods, 2026-10-13
- [2026-16296](https://policyrisk.com/federal-register/2026-16296): Substances Generally Recognized as Safe, 2026-08-11
- [2026-14073](https://policyrisk.com/federal-register/2026-14073): Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign E…, 2026-07-13
- [2026-13047](https://policyrisk.com/federal-register/2026-13047): Establishment Registration and Product Listing for Tobacco Products, 2026-06-29
- [2025-04978](https://policyrisk.com/federal-register/2025-04978): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-03-25
- [2025-01840](https://policyrisk.com/federal-register/2025-01840): Nonprescription Drug Product With an Additional Condition for Nonprescription Use, 2025-01-27

## Sources
- [2025-21071 on federalregister.gov](https://www.federalregister.gov/documents/2025/11/25/2025-21071/immunology-and-microbiology-devices-reclassification-of-nucleic-acid-based-test-systems-for-use-with)
- [2025-21071 as published (PDF)](https://www.govinfo.gov/content/pkg/FR-2025-11-25/pdf/2025-21071.pdf)

## Related
- [Previous: 2025-20949, Modification of Class E Airspace; Driggs/Reed Memorial Airport, Driggs, ID](https://policyrisk.com/federal-register/2025-20949)
- [Next: 2025-21087, Enhanced Transparency and Public Accountability of the Supervisory Stress Test…](https://policyrisk.com/federal-register/2025-21087)
- [All Federal Register documents](https://policyrisk.com/federal-register)

Source: PRIA, https://policyrisk.com/federal-register/2025-21071 (as of 2026-06-11).
